EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond class assumptions: a clinical decision framework for navigating drug-supplement interactions in oncology

Candy Tsourounis

Frontiers in Pharmacology · 03.11.2026 · 17

DOI: 10.3389/fphar.2026.1877127 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.11.2026. Verfasst von Candy Tsourounis. Beteiligte Einrichtung: Department of Clinical Pharmacy, Medication Outcomes Center, San Francisco, CA, United States. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dietary supplement use is common among patients with cancer, with nearly half reporting concurrent use alongside conventional therapy. Despite widespread use, drug–supplement interactions in oncology are often difficult to interpret due to heterogeneous evidence, outdated case reports, reliance on in vitro and animal data, and a traditional focus on drug class effects rather than drug-specific vulnerability. Translation of preclinical findings is further complicated by host factors such as inflammation, pharmacogenomic variability, and the gut microbiome. The purpose of this review is to provide a mechanistic overview of drug–supplement interactions in oncology and characterize the existing literature to support clinical decision-making.

Methods

This narrative review synthesizes current literature on pharmacokinetic and pharmacodynamic interactions between dietary supplements and anticancer therapies, focusing on key mechanistic domains, including drug metabolism (CYP450 and UDP-glucuronosyltransferase enzymes), transporter systems, and immune modulation, and clinically relevant uncertainty. Interaction risk was evaluated across major anticancer drug classes, including tyrosine kinase inhibitors, hormonal therapies, oral chemotherapies, and immune checkpoint inhibitors.

Results

Interaction vulnerability varies substantially by drug class but is not uniform across individual agents. Tyrosine kinase inhibitors have substantial interaction potential due to CYP3A4 dependence, exposure-response relationships, and, for some agents, narrow therapeutic margins, with vulnerability varying by agent. Hormonal therapies present mechanism-specific risks, particularly CYP2D6-mediated activation of tamoxifen. Oral chemotherapies demonstrate variable interaction potential, with capecitabine associated with increased bleeding risk and cyclophosphamide dependent on CYP-mediated activation. Immune checkpoint inhibitors are less susceptible to metabolic interactions but present interpretation challenges related to immune modulation and emerging microbiome-related evidence, where theoretical risks often exceed clinical evidence. Across drug classes, many reported interactions remain theoretical, are derived from non-clinical data, or lack standardized product verification, limiting clinical interpretation.

Conclusion

Drug–supplement interaction risk in oncology is best understood through a mechanism-based, drug-specific framework rather than isolated supplement-based or class-level approaches. A structured assessment incorporating drug metabolism, supplement activity, host factors, and clinical context may improve risk stratification and patient counseling, although management remains challenging in the absence of robust clinical data. Routine medication reconciliation and increased patient disclosure remain essential to minimizing avoidable harm and supporting safe, individualized cancer care.

Schlagwörter

Stichwörter der Autor:innen

CYP450 metabolismbotanicalsdietary supplementsdrug supplement interactionsimmune checkpoint inhibitorsoncologytyrosine kinase inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Medication Outcomes Center, San Francisco, CA, United States.
  • UCSF Osher Center for Integrative Health, San Francisco, CA, United States.

Zitieren

APA

Tsourounis, C. (2026). Beyond class assumptions: a clinical decision framework for navigating drug-supplement interactions in oncology. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1877127

Vancouver

Tsourounis C. Beyond class assumptions: a clinical decision framework for navigating drug-supplement interactions in oncology. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1877127

BibTeX
@article{Tsourounis2026,
  author = {Tsourounis, Candy},
  title = {Beyond class assumptions: a clinical decision framework for navigating drug-supplement interactions in oncology},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1877127}
}
Kostenlos starten →